Table 1.

Small Molecule Kinase Inhibitors

Name	Targets	Oncology Uses	Predictive Biomarkers
Dasatinib	BCR-ABL, c-KIT, PDGFR	CML, ALL
Imatinib	BCR-ABL, c-KIT, PDGFR	CML, ALL, GIST	c-Kit mutation, Philadelphia chromo-  some (bcr-abl)
Nilotinib	BCR-ABL	CML
Erlotinib	EGFR	NSCLC, pancreatic cancer	EGFR mutation
Gefitinib	EGFR, RET	NSCLC, medullary thyroid cancer	EGFR mutation, RET oncogene
Lapatinib	EGFR/HER-2	Breast cancer	HER-2
Sorafenib	c-RAF, VEGFR2, EGFR,  PDGFR	HCC, RCC
Sunitinib	VEGFR2, PDGFR, c-KIT	GIST, HCC, pancreatic neuroendocrine  tumors
Crizotinib	ALK, cMET	NSCLC	EML4-ALK translocation
Vemurafenib	BRAF	Melanoma	B-Raf mutation
Regorafenib	VEGF	CRC
Aflibercept	VEGF	CRC

ALK, analplastic lymphoma factor, ALL, acute lymphoblastic leukemia, BCR-ABL, breakpoint cluster region/the Abelson tyrosine, BRAF, v-raf murine sarcoma viral oncogene, c-KIT, tyrosine-protein kinase kit or mast/stem cell growth factor receptor, cMET, mesenchymal epithelial transition factor, CML, chronic myelogenous leukemia, c-RAF, RAF oncogene, CRC, colorectal carcinoma, EGFR, epidermal growth factor receptor, EML4, echinoderm microtubule-associated protein-like 4, GIST, gastrointestinal stromal tumors, HCC, hepatocellular carcinoma, HER2, antihuman epidermal growth factor receptor 2, NSCLC, non–small cell lung carcinoma, PDGFR, platelet-derived growth factor receptor, RCC, renal cell carcinoma, RET, ret proto-oncogene, VEGFR2, vascular endothelial growth factor receptor-2.